Kadcyla (trastuzumab emtansine)
Kadcyla (Trastuzumab Emtansine), also known as T-DM1, is a targeted antibody-drug conjugate (ADC) used to treat HER2-positive breast cancer. It combines the HER2-targeting properties of trastuzumab with a potent anticancer agent, allowing for precise delivery of chemotherapy directly to cancer cells while minimizing effects on healthy tissues.
Keytruda (Pembrolizumab)
Keytruda (Pembrolizumab) is a prescription immunotherapy medicine used to treat various types of cancer by helping the body's immune system recognize and fight cancer cells more effectively. It belongs to a class of medicines known as PD-1 inhibitors and is widely used in the treatment of melanoma, lung cancer, head and neck cancer, kidney cancer, bladder cancer, and several other malignancies.
Kisqali (ribociclib)
Kisqali (Ribociclib) is an oral targeted therapy used in the treatment of hormone receptor (HR)-positive, HER2-negative breast cancer. As a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, it works by slowing the growth and division of cancer cells, helping to delay disease progression and improve patient outcomes when used in combination with endocrine therapy.
Lenvima (lenvatinib)
Lenvima (Lenvatinib) is an oral targeted therapy used to treat several types of cancer, including thyroid cancer, liver cancer, kidney cancer, and endometrial cancer. It works by inhibiting multiple kinases involved in tumor growth and blood vessel formation, helping to slow cancer progression and reduce tumor development.
Lynparza (olaparib)
Lynparza (Olaparib) is an oral targeted therapy used to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with specific genetic mutations, including BRCA mutations. As a PARP inhibitor, it works by interfering with cancer cells' ability to repair damaged DNA, leading to the destruction of tumor cells while limiting the impact on healthy cells.
Opdivo (Nivolumab)
Opdivo (Nivolumab) is an advanced immunotherapy medication used to treat a variety of cancers by enhancing the body's immune response against cancer cells. As a PD-1 checkpoint inhibitor, Opdivo helps restore the immune system's ability to detect and attack tumors, making it an important treatment option in modern oncology.
Perjeta (pertuzumab)
Perjeta (Pertuzumab) is a targeted monoclonal antibody therapy used in the treatment of HER2-positive breast cancer. It works by blocking HER2 receptor signaling pathways that promote cancer cell growth, helping to slow disease progression and improve treatment outcomes when used in combination with other anti-cancer therapies.
Phesgo (pertuzumab/trastuzumab)
Phesgo (Pertuzumab/Trastuzumab) is a fixed-dose combination therapy used for the treatment of HER2-positive breast cancer. It combines two targeted monoclonal antibodies that work together to block HER2 signaling pathways, helping to slow tumor growth and improve treatment outcomes. Phesgo is administered as a convenient subcutaneous injection under the supervision of healthcare professionals.
Pomalyst/Imnovid (pomalidomide)
Pomalyst/Imnovid (Pomalidomide) is an oral immunomodulatory medicine used primarily for the treatment of multiple myeloma and certain related blood disorders. It works by enhancing the immune system's ability to fight cancer cells, inhibiting tumor growth, and helping to reduce disease progression in patients with advanced hematologic malignancies.
Reblozyl (luspatercept)
Reblozyl (Luspatercept) is an innovative erythroid maturation agent used to treat certain forms of anemia associated with blood disorders such as beta-thalassemia and myelodysplastic syndromes (MDS). It works by promoting the maturation of red blood cells, helping to increase hemoglobin levels and reduce the need for red blood cell transfusions in eligible patients.
Revlimid (Lenalidomide)
Revlimid (Lenalidomide) is an oral immunomodulatory medicine used in the treatment of multiple myeloma and certain blood disorders. It works by influencing the immune system, inhibiting the growth of abnormal cells, and helping to reduce the progression of disease while improving treatment outcomes.
Tafinlar+Mekinist
Tafinlar (Dabrafenib) + Mekinist (Trametinib) is a targeted combination therapy used to treat certain cancers with specific BRAF gene mutations, including melanoma, non-small cell lung cancer (NSCLC), and thyroid cancer. This dual-targeted approach blocks key pathways involved in cancer cell growth and survival, helping to slow disease progression and improve treatment outcomes.
